Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Alamar Biosciences launched the NULISAseq Immune 340 Panel, expanding its multiplexed immune profiling solution to measure approximately 340 immune-related proteins from a single sample. The new panel captures low-abundance targets such as checkpoint inhibitors and regulatory proteins that standard platforms often miss, supporting research in cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging.
Key figures
- Panel protein count
- 340
- Previous panel protein count
- 250
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.